Auriga Laboratories Announces EquityNet Research Initiates Coverage of Auriga Laboratories with "Buy" Rating and Projected 12-Month Share Price of $4.17.Report Cites Strong Competitive Advantages in Pharmaceutical Industry, Key Market Opportunities and Innovative Sales Strategies NORCROSS Norcross can refer to any of the following: Places United States
See OTC Bulletin Board (OTCBB). :ARGA ARGA Arkansas Rice Growers Association (North Little Rock, AR) ), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, today announced that equity analysis firm EquityNet Research has initiated paid research coverage of the Company with a detailed report that recommends a "Buy" rating, and projects a 12-month share price target of $4.17. In determining its valuation and projected share price appreciation for Auriga, EquityNet noted a number of core growth factors, including the Company's diverse intellectual property portfolio and brand-name pharmaceuticals for the multibillion-dollar respiratory, allergy allergy, hypersensitive reaction of the body tissues of certain individuals to certain substances that, in similar amounts and circumstances, are innocuous to other persons. Allergens, or allergy-causing substances, can be airborne substances (e.g. and cold markets. EquityNet highlighted Auriga's high-growth business model enabling it to rapidly acquire and develop proprietary brands in the prescription drug prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, marketplace, and then to maximize potential revenues through aggressive and broad intellectual property protection and innovative sales and marketing strategies. "While traditional pharmaceutical companies, with their shrinking pipelines, labor for years developing new drugs, Auriga's process allows it to quickly narrow down the huge field of potential revenue-generating candidates," wrote Equity Net Research analyst Randy The name Randy generally derives from the names Randall or Randolph (meaning wolf with a shield). Randy is used as a given name primarily in the US and Canada. Men known as Randy
Investment highlights pertaining per·tain intr.v. per·tained, per·tain·ing, per·tains 1. To have reference; relate: evidence that pertains to the accident. 2. to Auriga noted by EquityNet include: * Strong competitive advantages: The Company is pursuing a wide variety of indications, and works on reformulation of already approved drugs In the United States, the FDA approves drugs. Before a drug can be prescribed, it must undergo an extensive FDA approval process. This process involves first testing the drug on animals or in medical labs. , thus eliminating the need for lengthy and costly FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval. * Large collective market opportunity: Collectively, the illnesses targeted are some of the most common and affect literally millions of Americans each year. * Strong Management and Scientific Advisory Teams. The Company's world-class management and advisory team have expertise in drug delivery, innovative sales and marketing and drug development, coming from such firms and institutions as SmithKline Beecham, First Horizon Pharmaceutical Corp., Cardinal Health <includeonly></includeonly> Cardinal Health (NYSE: CAH) is a premier, global healthcare company dedicated to making healthcare safer and more productive. Overview Headquartered in Dublin, Ohio, Cardinal Health, Inc. , and the Squibb Institute for Medical Research. * Increased Market Visibility. By initially focusing on common brand names such as Levall[TM], Auriga is gaining rapid market visibility and legitimacy LEGITIMACY. The state of being born in wedlock; that is, in a lawful manner. 2. Marriage is considered by all civilized nations as the only source of legitimacy; the qualities of husband and wife must be possessed by the parents in order to make the offspring . The Company also recently provided revenue guidance for FY 06 and 07, the latter of which we have used as a basis for our valuation target. Among Auriga's key initiatives is the Company's recent implementation of an innovative plan to significantly expand its sales force through a commission-only structure, as opposed to the industry's standard salary-plus-commission model. Auriga implemented the sales force structure to significantly increase the number of sales representatives to maximize potential revenues -- while minimizing costs. "Management estimates that this strategy will attract the best performers in the business and that fielding the same number of representatives under the old compensation structure would have cost the Company close to $20 million annually," wrote Mr. Lewis. Additional competitive advantages described in the report include: * The Company has a diverse pharmaceutical portfolio, thus reducing dependence on any one drug for its success. * The Company's Initial focus has been on drugs that are already approved and overlooked by the big Pharmas, potentially minimizing competition and eliminating the need to go head-to-head with larger industry players. * Auriga's dynamic business model allows it to quickly pursue potential high-margin products and adapt to industry changes. * The management team and Scientific Advisory Board are made up of knowledgeable, deeply experienced people, some spending years at least one comparable company we chose for our valuation. Chief Executive Officer, Philip S. Pesin said, "Auriga has engaged EquityNet Research to conduct a thorough, responsibly researched and credible analysis of Auriga and the market. Though it is fee-based research, we believe the EquityNet report presents an engaging, balanced and detailed view of our company and its diverse product portfolio and brand-name pharmaceuticals already being sold around the country." Auriga has compensated EquityNet Research to conduct a comprehensive and objective third party research report, and the resulting analysis and assessment is EquityNet's own independent work product. Auriga did not participate in the creation of the conclusions in the report, nor its price growth projections. The full report, produced under compensation terms described below, can be found at http://www.equitynet.net/. About Auriga Laboratories(TM) Auriga Laboratories(TM) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing and advanced in-house In-house In the context of general equities, keeping an activity within the firm. For example, rather than go to the marketplace and sell a security for a client to anyone, an attempt is made to find a buyer to complete the transaction with the firm. drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the Extendryl[R] and Levall[R] families of prescription products, indicated for relief of symptoms associated with a range of acute respiratory diseases Noun 1. respiratory disease - a disease affecting the respiratory system respiratory disorder, respiratory illness adult respiratory distress syndrome, ARDS, wet lung, white lung - acute lung injury characterized by coughing and rales; inflammation of the . Auriga's product portfolio also consists of Aquoral(TM) for the treatment of Xerostomia xerostomia /xe·ro·sto·mia/ (zer?o-sto´me-ah) dryness of the mouth due to salivary gland dysfunction. xe·ro·sto·mi·a n. . Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/auriga/. For an informational video overview, visit http://www.trilogy-capital.com/tcp/auriga/video.html. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/auriga/quote.html. Compensation Disclosures EquityNet Research is an independent research firm and has been compensated $7,500 by the subject company for this research report. The information contained herein has been obtained from sources which are believed to be reliable, but the accuracy or completeness of the contents cannot be guaranteed. Any opinions and/or projections expressed herein are solely of the writer and are subject to change without notice. This report under no circumstances CIRCUMSTANCES, evidence. The particulars which accompany a fact. 2. The facts proved are either possible or impossible, ordinary and probable, or extraordinary and improbable, recent or ancient; they may have happened near us, or afar off; they are public or is to be construed as an offer to sell or the solicitation solicitation In criminal law, the act of asking, inducing, or directing someone to commit a crime. The person soliciting another becomes an accomplice to the crime. The term also refers to the act of obtaining bribes, as well as to the crime of a prostitute who offers sexual of an offer to buy any securities. This report contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. including expressions of belief, expectation, contemplation Contemplation Compleat Angler, The Izaak Walton’s classic treatise on the Contemplative Man’s Recreation. [Br. Lit.: The Compleat Angler] Thinker, The sculpture by Rodin, depicting contemplative man. , estimation estimation In mathematics, use of a function or formula to derive a solution or make a prediction. Unlike approximation, it has precise connotations. In statistics, for example, it connotes the careful selection and testing of a function called an estimator. and other expressions not relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc historical facts and circumstances. These forward-looking statements are subject to numerous risks and uncertainties that may cause such statements not to prove accurate. Any recommendations contained in this report may not be suitable for all investors. Any investment recommendations in this report contain a high degree of risk and a prospective investor is encouraged to review in detail the company's prospectus, SEC filings, and/or other additional information. Any projections or estimates herein made assume certain economic and industry conditions and parameters subject to change. Forward-Looking Statements The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Securities and Exchange Commission and other regulatory authorities Noun 1. regulatory authority - a governmental agency that regulates businesses in the public interest regulatory agency administrative body, administrative unit - a unit with administrative responsibilities . Statements regarding the regulatory status and/or regulatory compliance of our products, our ability to secure additional financing, our ability to sustain market acceptance for our products, our dependence on collaborators, our ability to find and execute strategic transactions, or potential exposure to litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , our exposure to product liability claims, and our prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion